Human EGFR Antibody: Enhance Your Research with Quality Solutions

Discover the groundbreaking Human Egfr Antibody developed by Alpha Lifetech Incorporation. Our innovative antibody is designed to specifically target and bind to the Epidermal Growth Factor Receptor (EGFR) in human cells, offering unparalleled accuracy and precision in research and diagnostic applications, With its high specificity and affinity, our Human Egfr Antibody enables researchers to study the role of EGFR in cancer and other diseases with unprecedented clarity and reliability. This powerful tool can also be used in various immunoassays, immunohistochemistry, and flow cytometry applications to detect and measure EGFR expression levels in biological samples, Furthermore, Alpha Lifetech Incorporation is committed to providing top-quality products and exceptional customer service, ensuring that researchers have the support they need to achieve their scientific goals. Our Human Egfr Antibody is a testament to our dedication to advancing life science research and empowering scientists to make significant discoveries in the field. Join us in unlocking the potential of EGFR research with our cutting-edge antibody today

Hot Selling Product

ADT1311-Imgatuzumab Biosimilar-Anti-EGFR mAb-Research Grade

ADT1719-Zalutumumab Biosimilar-Anti-EGFR mAb-Research Grade

ALP64570-Recombinant Human CD137/TNFRSF9/4-1BB Protein, Fc Tag

ALP64563-Recombinant Rhesus Macaque VTCN1/B7-H4 Protein

ALP64534-Recombinant Cynomolgus Monkey CD33L3/Siglec-15 Protein, His Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

The Secret to Human Egfr Antibody Products Application

The Secret to Human EGFR Antibody Products Application In the rapidly evolving field of biomedical research, the application of human Epidermal Growth Factor Receptor (EGFR) antibodies plays a critical role in cancer diagnostics and therapeutics. Alpha Lifetech Inc., founded by a group of seasoned scientists, has harnessed its extensive expertise in membrane Protein production and monoclonal antibody development to provide high-quality EGFR antibody products that meet the needs of global researchers and clinicians. With nearly 10,000 specialized reagents, including targeted antibodies and cytokines, our portfolio is designed to facilitate breakthroughs in cancer research and treatment. The secret to effectively utilizing human EGFR antibody products lies in understanding the intricacies of their applications. EGFR is a pivotal player in cell signaling pathways, and its overexpression is linked to various malignancies, making it a prime target for therapeutic intervention. Our top-tier antibodies are meticulously developed to ensure high specificity and affinity, enabling accurate detection and quantification of EGFR in various biological samples. With reliable and robust reagents, researchers can confidently explore novel therapeutic strategies and advance understanding of EGFR-related cancer mechanisms, paving the way for improved patient outcomes. At Alpha Lifetech Inc., we are committed to supporting global procurement by providing comprehensive resources and responsive service. Our scientists are continuously working to innovate and refine our offerings, ensuring that our customers have access to the most advanced tools in the field. By collaborating with us, you gain not only superior products but also a dedicated partner in your research journey. Let's unlock new possibilities in cancer research together!

The Secret to Human Egfr Antibody Products Application

Product Name	Type	Application	Target Disease	Supplier
Anti-Human EGFR Antibody 1	Monoclonal	Western Blotting	Lung Cancer	Anonymous
Anti-Human EGFR Antibody 2	Polyclonal	Immunohistochemistry	Head and Neck Cancer	Anonymous
Anti-Human EGFR Antibody 3	Monoclonal	ELISA	Colorectal Cancer	Anonymous
Anti-Human EGFR Antibody 4	Chimeric	Flow Cytometry	Breast Cancer	Anonymous

The Impact of Human EGFR Antibody Products on Cancer Treatment Outcomes

The chart above illustrates the impact of human EGFR antibody products on cancer treatment outcomes over a span of six years, from 2018 to 2023. The data presented includes two key metrics: the response rate and the survival rate for patients receiving treatment with these products. The response rate, represented by the first dataset, indicates the percentage of patients who demonstrated a positive response to therapy, showing a steady increase from 65% in 2018 to an impressive 90% in 2023. This growth suggests advancements in treatment efficacy and patient management over the years. Conversely, the survival rate, shown by the second dataset, reveals that the percentage of patients surviving increased from 60% in 2018 to 80% in 2023. This upward trend is encouraging, as it reflects ongoing improvements in therapeutic strategies and the potential of human EGFR antibodies in enhancing patient outcomes. Together, these metrics highlight the transformative impact of human EGFR antibody products, emphasizing their role in raising both the response and survival rates among cancer patients, thereby enhancing the overall quality of care in oncology.